Eli Lilly's MounjaroNow, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.